- Business Wire•17 days ago
Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m.
- Business Wire•29 days agoVerastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
Verastem, Inc., today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.
- Business Wire•last month
Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.
VSTM : Summary for Verastem, Inc. - Yahoo Finance
Verastem, Inc. (VSTM)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.80 x 700|
|Ask||1.45 x 1000|
|Day's Range||1.17 - 1.23|
|52 Week Range||1.05 - 1.93|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|